PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
J Clin Investig Dermatol. Author manuscript; available in PMC 2017 September 19.
Published in final edited form as:
J Clin Investig Dermatol. 2017 January; 5(1): 10.13188/2373-1044.1000036.
Published online 2017 January 10.
PMCID: PMC5603292
NIHMSID: NIHMS843032

Clinical Characteristics of Non-Melanoma Skin Cancers Recurring within 5 years after Mohs Micrographic Surgery: Single Institution Retrospective Chart Review

Abstract

Background

Mohs micrographic surgery (MMS) is used to treat certain high-risk non-melanoma skin cancers (NMSC) due to its high cure rate. However, clinical recurrences do occur in a small number of cases.

Objective

We examined specific clinical characteristics associated with NMSC recurrences following MMS.

Methods

We employed a retrospective chart review of the 1467 cases of NMSC that underwent MMS at UC San Diego from January 1, 2008 through December 31, 2009. A total of 356 cases were excluded due to lack of follow-up.

Results

Five (0.45%) of 1111 cases developed recurrences of NMSC at the site of MMS. There were 741 cases of basal cell carcinomas (BCC); 3 were recurrences (0.40%). There were 366 cases of squamous cell carcinomas (SCC); 2 were recurrences (0.55%). Review of MMS histopathology of these recurrent tumors showed that there were no errors or difficulty with the processing or interpretation of the slides.

Conclusion

Five-year recurrence rate of NMSC following MMS at our institution is below the reported average. Our retrospective chart review identified specific clinical characteristics associated with NMSC recurrence including a history of smoking, anatomical location on the cheeks, ears or nose, and a history of immunosuppression for SCCs.

Introduction

Over one million new cases of non-melanoma skin cancers (NMSC) are diagnosed annually in the United States, and the prevalence of skin cancer is five times higher than that of breast or prostate cancer [1,2]. The incidence of NMSC is increasing worldwide, especially in the United States, Europe and Australia, most likely due to a growing, aging population as well as prolonged ultra violate exposure [3,4].

NMSC most commonly include basal cell carcinomas (BCC) and squamous cell carcinomas (SSC), and many factors influence their development. NMSC such as BCC and SCC most frequently occur on the face and neck due to longitudinal UV exposure [5]. Additionally, patients who are immunosuppressed and/or are organ transplant recipients have significantly increased risk of developing NMSC. There is a 65 to 250-fold increase in developing squamous cell carcinoma and a 10-fold increase in basal cell carcinoma in these patients. In addition to developing higher numbers of NMSC, recent studies have shown that many immunosuppressed patients have NMSCs with aggressive subclinical extensions [6,7]. Associations have also been found between smoking and squamous cell carcinomas, with a higher risk in current smokers than former smokers [8].

The gold standard for the removal of a high risk NMSC is Mohs micrographic surgery (MMS) because of its low recurrence rate and tissue sparing technique. Although there are a number of treatment modalities for NMSC including surgical excision and electrodessication and curettage, MMS continues to be the most advantageous. Studies have shown cure rates for surgical excision as 95% for NMSC less than 2 cm and 84% for electrodessication and curettage for NMSC greater than 2 cm [9]. Unlike other modalities, MMS offers a superior cure rate of 99% within 5 years for primary BCCs, and slightly lower cure rate for primary SCCs [10]. Further analysis has shown the cost effectiveness of MMS in treating high risk NMSC since very high cure rates limit subsequent procedures while maximizing tissue preservation and cosmesis [10,11].

Recurrence rates following MMS have been variable as multiple studies express different recurrence rates. Primary BCCs have about a 1% risk of recurring [10-13]. However, recurrent BCCs have a higher recurrence rate of 10.4% following MMS [6]. Primary SCCs have a recurrence rate of about 2 to 3%, while recurrent SCCs have a 6-10% recurrence rate following MMS [14,15].

In this study, we aim to identify risk factors that lead to NMSC recurrences.

Methods

We reviewed the medical records of 1467 cases of MMS for NMSC performed at the University of California, San Diego (UCSD) Dermatologic and Mohs Micrographic Surgery Center from January 1st, 2008 through December 31st 2009. A retrospective chart review was used to identify cases of NMSC recurrence within 5 years of MMS at our institution. In this IRB approved study, there were 611 cases in which patients lacked 5 years of follow-up at UCSD post MMS. They were contacted via telephone and asked if they had further treatments at the site of the original MMS. Of the 611 cases not followed-up at UCSD, 346 were unable to be reached over the phone (loss to follow-up, new phone numbers, or death) and were excluded from the study. This included 128 SCCs, 217 BCCs, and 1 atypical fibroxanthoma. Three patients who answered the phone were unable to say with certainty if they had further treatments or not on the same location of the initial MMS, and were also excluded from the study. Seven patients had incomplete information in their charts to determine if they had a recurrence in their NMSC, and these cases were excluded. Therefore, 356 cases were excluded from the study.

Retrospective chart review of the 1111 cases included in the study was performed and further subdivided into 741 BCC, 366 SCC and 4 other unusual cutaneous tumors (dermatofibrosarcoma protuberans, porocarcinoma, atypical fibroxanthoma, and sebaceous carcinoma). Recurrent cases were defined by the same type of NMSC, occurring at the same site as the previous MMS. For the recurrent cases, we gathered information regarding the patients’ NMSC histopathology, smoking status, immunosuppression, anatomical location and time to recurrence. Slides from the initial MMS were also reviewed to ensure that there was no error or difficulty with slide interpretation or processing of the slides that would lead to the recurrence.

Results

Five (0.45%) cases of recurrent NMSC within 5 years were found in the 1111 cases of MMS performed in 2008 and 2009. All five patients underwent MMS within a few months of their NMSC diagnosis. The time to recurrence ranged from 11 to 38 months post initial MMS with an average of 23.6 months. A summary of the data collected can be found in Table 1.

Table 1
Summary of results for patients with recurrent NMSC.

Demographics of patients with recurrences

All 5 patients (3 male and 2 female) with recurrences were between the ages of 60 and 96. The average age for the initial MMS in these patients was 73 and the average age of MMS for their recurrence was 74.6.

Histopathology of NMSC-BCC, SCC and other subtypes

There were 741 cases of BBC, 366 cases of SCC and 4 cases of other unusual types of NMSC. There were no recurrences found in the other usual cutaneous tumors including dermatofibrosarcoma protuberans, atypical fibroxanthoma, porocarcinoma and sebaceous carcinoma. There were 3 recurrences of BCC (0.40%) and 2 recurrences of SCC (0.55%).

Two of the three BCC recurrences arose from low-risk nodular BCCs. One of the two SCC recurrences arose from a SCC in situ while the other arose from a biopsy-proven SCC in situ, which was upstaged to a SCC at the time of initial MMS.

The initial MMS histopathology of the recurrent cases was reviewed and no errors or difficulty were noted with the processing or interpretation of the slides.

Immune status

Both of the SCC recurrences occurred in immunosuppressed patients (one patient with history of lung transplant and another with history of chronic lymphocytic leukemia). The three patients with BCC recurrences were not immunosuppressed.

Anatomic distribution of recurrences

All recurrent cases of NMSC were located on the face. Four of the five recurrences involved the left side of patients’ faces, specifically, the left medial cheek, left auricular helix, left preauricular cheek area, and left mandibular cheek. The final recurrence occurred on the right nasal ala (Figure 1).

Figure 1
Anatomical location of recurrent NMSC.

Smoking status

Three patients with recurrences also had a history of cigarette smoking. They smoked 0.75 packs per day for 17 years, 1 pack a day for 4 years, and 0.75 packs a day for 15 years.

Mohs stages and final surgical margins

The number of stages taken for MMS ranged from 1 to 5 (mean 2.6 stages) initially in patients with recurrences, and from 2 to 4 stages (mean 2.6 stages) for their recurrence. Their final postoperative Mohs surgical margins from the longer axis ranged from 2 to 21 mm (mean 12.2 mm) for the initial NMSC, and from 4 to 56 mm (mean 17.8 mm) for the recurrences. Aggressive subclinical extensions (ASE), defined as greater than 3 MMS stages and greater than 1.0 cm final surgical margins, were found in two patients with SCC recurrences and two patients with BCC recurrences as shown in Table 1. Two of the patients had ASE in their initial surgery and two had them in their recurrent surgery.

Discussion

Our single institution retrospective study revealed a lower than historical recurrence rate in non-melanoma skin cancers after Mohs micrographic surgery. Only 5 (0.45%) of the 1111 cases of MMS performed in 2008 and 2009 had a recurrence within 5 years. Further follow up with these five cases showed no evidence of another recurrence following the second MMS. The range of further follow up for these patients was 12 to 67 months post-MMS for the recurrence (mean 47.4 months). Review of MMS histopathology of these recurrent tumors showed that there were no errors or difficulty with the processing or interpretation of the slides.

There are reports of histologic subtypes being a risk factor for recurrence [16,17]. Our study did not show a correlation between aggressive histopathologic subtypes of NMSC and recurrence.

Immunosuppressed status, including history of solid organ transplant and hematologic malignancies, has been linked to SCC development and aggressive subclinical extensions [18,19] due to their chronic immunosuppressed status and decreased cutaneous immunosurveillance [6,7]. The two patients with SCC recurrences in our study were immunosuppressed (lung transplant and chronic lymphocytic leukemia).

We identified specific clinical characteristics associated with NMSC. All five of the recurrent cases of NMSC were localized to the face, specifically the upper cheek, ear, pre-auricular area and nose (Figure 1), with the final case located partially in the H zone and extending to the cheek. These findings are consistent with other reports in the literature of recurrences following MMS occurring most often in the H zone of the face [20].

A history of smoking was found in 60% of our recurrent cases. There have been several studies showing positive associations between cigarette smoking and development of NMSCs, especially SCC development [21-23]. However, other studies failed to show positive associations between smoking and NMSC development [24,25]. Cigarette smoking as a risk factor for recurrent NMSC has not been studied, and we have found an association between smoking and recurrent NMSC in our study.

Four out of five of the NMSC recurrences were found to have aggressive subclinical extensions (ASE) during the first or recurrent surgery. Both patients with SCC recurrences had ASE and two of the three BCC recurrences had ASE. It is known that immunosuppressed patients, especially those with solid organ transplants are more likely to have NMSC with ASE [7]. This is in accordance with our data as both patients with SCC had ASE and were immunocompromised.

A limitation of this study is that it is a single institution retrospective study that analyzed data of only a two-year period. Since recurrences are rare, further longitudinal and multi-center studies are also warranted to further identity risk factors for NMSC recurrences after MMS.

Acknowledgments

The project described was partially supported by the National Institutes of Health, Grant 5T35HL007491. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

References

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, et al. Cancer statistics 2004. CA Cancer J Clin. 2004;54:8–29. [PubMed]
2. Stern RS. Prevalence of a history of skin cancer in 2007 results of an incidence-based model. Arch Dermatol. 2010;146:279–282. [PubMed]
3. Samarasinghe V, Madan V. Nonmelanoma skin cancer. J Cutan Aesthet Surg. 2012;5:3–10. [PMC free article] [PubMed]
4. Trakatelli M, Ulrich C, del Marmol V, Euvrard S, Stockfleth E, et al. Epidemiology of nonmelanoma skin cancer (NMSC) in Europe: accurate and comparable data are needed for effective public health monitoring and interventions. Br J Dermatol. 2007;156(Suppl 3):1–7. [PubMed]
5. Surdu S, Fitzgerald EF, Bloom MS, Boscoe FP, Carpenter DO, et al. Occupational exposure to ultraviolet radiation and risk of non-melanoma skin cancer in a multinational European study. PLoS One. 2013;8:e62359. [PMC free article] [PubMed]
6. Goldenberg A, Ortiz A, Kim SS, Jiang SB. Squamous cell carcinoma with aggressive subclinical extension: 5-year retrospective review of diagnostic predictors. J Am Acad Dermatol. 2015;73:120–126. [PMC free article] [PubMed]
7. Song SS, Goldenberg A, Ortiz A, Eimpunth S, Oganesyan G, et al. Nonmelanoma skin cancer with aggressive subclinical extension in immunosuppressed patients. JAMA Dermatol. 2016;152:683–690. [PubMed]
8. De Hertog SA, Wensveen CA, Bastiaens MT, Kielich CJ, Berkhout MJ, et al. Relation between smoking and skin cancer. J Clin Oncol. 2001;19:231–238. [PubMed]
9. Lewin JM, Carucci JA. Advances in the management of basal cell carcinoma. F1000Prime Rep. 2015;7:53. [PMC free article] [PubMed]
10. Tierney EP, Hanke CW. Cost effectiveness of Mohs micrographic surgery: review of the literature. J Drugs Dermatol. 2009;8:914–922. [PubMed]
11. Kauvar AN, Cronin T, Jr, Roenigk R, Hruza G, Bennett R, et al. Consensus for nonmelanoma skin cancer treatment: basal cell carcinoma, including a cost analysis of treatment methods. Dermatol Surg. 2015;41:550–571. [PubMed]
12. Català A, Garces JR, Alegre M, Gich IJ, Puig L. Mohs micrographic surgery for basal cell carcinomas: results of a Spanish retrospective study and Kaplan-Meier survival analysis of tumour recurrence. J Eur Acad Dermatol Venereol. 2014;28:1363–1369. [PubMed]
13. Alam M, Desai S, Nodzenski M, Dubina M, Kim N, et al. Active ascertainment of recurrence rate after treatment of primary basal cell carcinoma (BCC) J Am Acad Dermatol. 2015;73:323–325. [PubMed]
14. Leibovitch I, Huilgol SC, Selva D, Hill D, Richards S, et al. Cutaneous squamous cell carcinoma treated with Mohs micrographic surgery in Australia I. Experience over 10 years. J Am Acad Dermatol. 2005;53:253–260. [PubMed]
15. Rowe DE, Carroll RJ, Day CL., Jr Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol. 1992;26:976–990. [PubMed]
16. Lang PG, Jr, Maize JC. Histologic evolution of recurrent basal cell carcinoma and treatment implications. J Am Acad Dermatol. 1986;14(2 Pt 1):186–196. [PubMed]
17. Clayman GL, Lee JJ, Holsinger FC, Zhou X, Duvic M, et al. Mortality risk from squamous cell skin cancer. J Clin Oncol. 2005;23:759–765. [PubMed]
18. Herman S, Rogers HD, Ratner D. Immunosuppression and squamous cell carcinoma: a focus on solid organ transplant recipients. Skinmed. 2007;6:234–238. [PubMed]
19. Wong J, Breen D, Balogh J, Czarnota GJ, Kamra J, et al. Treating recurrent cases of squamous cell carcinoma with radiotherapy. Curr Oncol. 2008;15:229–233. [PMC free article] [PubMed]
20. Chren MM, Torres JS, Stuart SE, Bertenthal D, Labrador RJ, et al. Recurrence after treatment of nonmelanoma skin cancer: a prospective cohort study. Arch Dermatol. 2011;147:540–546. [PMC free article] [PubMed]
21. Aubry F, MacGibbon B. Risk factors of squamous cell carcinoma of the skin. A case-control study in the Montreal region. Cancer. 1985;55:907–911. [PubMed]
22. De Hertog SA, Wensveen CA, Bastiaens MT, Kielich CJ, Berkhout MJ, et al. Relation between smoking and skin cancer. J Clin Oncol. 2001;19:231–238. [PubMed]
23. Boyd AS, Shyr Y, King LE., Jr Basal cell carcinoma in young women: an evaluation of the association of tanning bed use and smoking. J Am Acad Dermatol. 2002;46:706–709. [PubMed]
24. Freedman DM, Sigurdson A, Doody MM, Mabuchi K, Linet MS. Risk of basal cell carcinoma in relation to alcohol intake and smoking. Cancer Epidemiol Biomarkers Prev. 2003;12:1540–1543. [PubMed]
25. Odenbro A, Bellocco R, Boffetta P, Lindelof B, Adami J. Tobacco smoking, snuff dipping and the risk of cutaneous squamous cell carcinoma: a nationwide cohort study in Sweden. Br J Cancer. 2005;92:1326–1328. [PMC free article] [PubMed]